What is Paradigm Biopharmaceuticals Limited (PAR) Stock Price?
The live share price and session change for Paradigm Biopharmaceuticals Limited (PAR) are shown in the TradingView quote on this page.
PAR Stock Price, Valuation & Chart | Paradigm Biopharmaceuticals Limited
PAR Historical price chart
PAR Key Stats
Fair Value
Disclaimer
Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.
Market Capitalization143.81M
PE Ratio-1.58
EPS-0.15
Trading Volume2.80M
Today's High/Low0.26/0.23
Dividend Yield0.00
52 Week High/Low0.47/0.14
Shares Outstanding599.19M
PAR Financial Statement
PAR Analyst ratings
Buy
Strong buy
0
Buy
1
Hold
0
Sell
0
Strong sell
0
Based on 1 analyst giving stock ratings to PAR in the past 3 months.
PAR Analysis & performance metrics
PAR Company profile
Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers…
PAR Management team
Name
Position
Beverley Huttmann
Commercial Head
Paul John Rennie BSc, Grad Dip, MBM, MSTC
Founder, MD & Executive Chairman
Abby Macnish Niven B.Com., B.Sc., C.F.A.CFO
Company Secretary & Chief Financial Officer
Michelle Coffey
Global Head of Regulatory Affairs
Mukesh Ahuja
Global Clinical Head of OA
Simon WhiteCTO
Director of Investor Relations
Michael Imperiale
Global Head of Drug Safety & MPS
Ravi Krishnan
Chief Scientific Officer
Name
Position
Beverley Huttmann
Commercial Head
Paul John Rennie BSc, Grad Dip, MBM, MSTC
Founder, MD & Executive Chairman
Abby Macnish Niven B.Com., B.Sc., C.F.A.CFO
Company Secretary & Chief Financial Officer
Michelle Coffey
Global Head of Regulatory Affairs
Mukesh Ahuja
Global Clinical Head of OA
Simon WhiteCTO
Director of Investor Relations
Michael Imperiale
Global Head of Drug Safety & MPS
Ravi Krishnan
Chief Scientific Officer
Management Team
Beverley Huttmann
Commercial Head
Paul John Rennie BSc, Grad Dip, MBM, MSTC
Founder, MD & Executive Chairman
Abby Macnish Niven B.Com., B.Sc., C.F.A.CFO
Company Secretary & Chief Financial Officer
Michelle Coffey
Global Head of Regulatory Affairs
Mukesh Ahuja
Global Clinical Head of OA
Simon WhiteCTO
Director of Investor Relations
Michael Imperiale
Global Head of Drug Safety & MPS
Ravi Krishnan
Chief Scientific Officer
Management
Beverley Huttmann
Commercial Head
Paul John Rennie BSc, Grad Dip, MBM, MSTC
Founder, MD & Executive Chairman
Abby Macnish Niven B.Com., B.Sc., C.F.A.CFO
Company Secretary & Chief Financial Officer
Michelle Coffey
Global Head of Regulatory Affairs
Mukesh Ahuja
Global Clinical Head of OA
Simon WhiteCTO
Director of Investor Relations
Michael Imperiale
Global Head of Drug Safety & MPS
Ravi Krishnan
Chief Scientific Officer
Total 8 executives
PAR Frequently asked questions
Why is the Paradigm Biopharmaceuticals Limited (PAR) stock price going up or down today?
The stock price of Paradigm Biopharmaceuticals Limited (PAR) can change with earnings, company news, and overall market sentiment. Paradigm Biopharmaceuticals Limited operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live TradingView quote on this page together with the chart and key stats.
Is the Paradigm Biopharmaceuticals Limited stock expensive at its current price?
Whether Paradigm Biopharmaceuticals Limited looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for PAR on this page is -1.58. EPS on this page is -0.15. Compare those figures with peers and growth expectations before deciding if the current Paradigm Biopharmaceuticals Limited price is justified.
How has the stock price of Paradigm Biopharmaceuticals Limited (PAR) performed historically?
Historical performance for Paradigm Biopharmaceuticals Limited (PAR) is shown on the price chart on this page. Review multi-period moves alongside volume to see how PAR reacted to past earnings and market events.
Should I buy Paradigm Biopharmaceuticals Limited (PAR) stock, at this price?
Buying Paradigm Biopharmaceuticals Limited (PAR) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.